Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow

Molecular Therapy

Volumn 6, Issue 1, 2002, Pages 19-29

  Pan, Dao ^a   Gunther, Roland ^b   Duan, Weiming ^a   Wendell, Steve ^a   Kaemmerer, William ^a   Kafri, Tal ^c   Verma, Inder M ^d   Whitley, Chester B ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

Biodistribution; Bone marrow transduction; Gene therapy; Germline transmission; Lentiviral vector; Real time PCR; Toxicity

Indexed keywords

GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW; CONTROLLED STUDY; CYTOMEGALOVIRUS; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRAVENOUS ADMINISTRATION; LIVER; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; SPLEEN; STEM CELL; TISSUE DISTRIBUTION; TOXICITY; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALIA; CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS;

EID: 0036665573     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2002.0630     Document Type: Article

References (49)

1. Food and Drug Administration (1991). Points to consider in human somatic cell therapy and gene therapy. http://www.fda.gov/cber/gdlns/ptcsomat.pdf.
2. Food and Drug Administration (1998). Guidance for industry: guidance for human somatic cell therapy and gene therapy. http://www.fda.gov/cber/gdlns/somgene.pdf.
3. Pilaro, A. M., and Serabian, M. A. (1999). Preclinical development strategies for novel gene therapeutic products. Toxicol. Pathol. 27: 4-7.
4. Verdier, F., and Descotes, J. (1999). Preclinical safety evaluation of human gene therapy products. Toxicol. Sci. 47: 9-15.
5. Amado, R. G., and Chen, I. S. (1999). Lentiviral vectors-the promise of gene therapy within reach? Science 285: 674-676.
6. Lever, A. M. (2000). Lentiviral vectors: progress and potential. Carr. Opin, Mol. Ther. 2: 488-496.
7. Podsakoff, G. M. (2001). Lentiviral vectors approach the clinic but fall back: National Institutes of Health Recombinant DNA Advisory Committee review of a first clinical protocol for use of a lentiviral vector. Mol. Ther. 4: 282-283.
8. Naldini, L., Blomer, U., Gage, F. H., Trono, D., and Verma, I. M. (1996). Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. USA 93: 11382-11388.
9. Blomer, U., et al. (1997). Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J. Virol. 71: 6641-6649.
10. Kafri, T., Blomer, U., Peterson, D. A., Gage, F. H., and Verma, I. M. (1997). Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat. Genet. 17: 314-317.
11. + cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 283: 682-686.
12. Johnson, L. G., Olsen, J. C., Naldini, L., and Boucher, R. C. (2000). Pseudotyped human lentiviral vector-mediated gene transfer to airway epithelia in vivo. Gene Ther. 7: 568-574.
13. Naldini, L., et al. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267.
14. Reiser, J., et al. (1996). Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc. Natl. Acad. Sci, USA 93: 15266-15271.
15. Kim, V. N., Mitrophanous, K., Kingsman, S. M., and Kingsman, A. J. (1998). Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J. Virol, 72: 811-816.
16. Dull, T., et al. (1998). A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72: 8463-8471.
17. Miyoshi, H., Blomer, U., Takahashi, M., Gage, F. H., and Verma, I. M. (1998). Development of a self-inactivating lentivirus vector. J. Virol. 72: 8150-8157.
18. Romano, G., Michell, P., Pacilio, C., and Giordano, A. (2000). Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications. Stem Cells 18: 19-39.
19. Miyoshi, H., Takahashi, M., Gage, F. H., and Verma, I. M. (1997). Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc. Natl. Acad Sci. USA 94: 10319-10323.
20. Woods, N. B., et al. (2001). Lentiviral-mediated gene transfer into haematopoietic stem cells. J. Intern. Med. 249: 339-343.
21. Gordon, J. W. (1998). Germline alteration by gene therapy: assessing and reducing the risks. Mol. Med. Today 4: 468-470.
22. Orlando, C., Pinzani, P., and Pazzagli, M. (1998). Developments in quantitative PCR. Clin. Chem. Lab. Med. 36: 255-269.
23. Heid, C. A., Stevens, J., Livak, K. J., and Williams, P. M. (1996). Real-time quantitative PCR. Genome Res. 6: 986-994.
24. . Becker, K., Pan, D., and Whitley, C. B. (1999). Real-time quantitative polymerase chain reaction to assess gene transfer. Hum. Gene Ther. 10: 2559-2566.
25. Schnitzlein, W. M., and Reichmann, M. E. (1985). Characterization of New Jersey vesicular stomatitis virus isolates from horses and black flies during the 1982 outbreak in Colorado. J. Virol. 142: 426-431.
26. Fields, B. N., and Hawkins, K. (1967). Human infection with the virus of vesicular stomatitis during an epizootic. N. Engl. J. Med. 277: 989-994.
27. Coll, J. M. (1995). The glycoprotein G of rhabdoviruses. Arch. Virol. 140: 827-851.
28. Albritton, L. M., Tseng, L., Scadden, D., and Cunningham, J. M. (1989). A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and confers susceptibility to virus infection. Cell 57: 659-666.
29. Sattentau, Q. J., Dalgleish, A. G., Weiss, R. A., and Beverley, P. C. (1986). Epitopes of the CD4 antigen and HIV infection. Science 234: 1120-1123.
30. Mastromarino, P., Conti, C., Goldoni, P., Hauttecoeur, B., and Orsi, N. (1987). Characterization of membrane components of the erythrocyte involved in vesicular stomatitis virus attachment and fusion at acidic pH. J. Gen. Virol. 68: 2359-2369.
31. Konieczko, E. M., Whitaker-Dowling, P. A., and Widnell, C. C. (1994). Membrane fusion as a determinant of the infectibility of cells by vesicular stomatitis virus. J. Virol. 199: 200-211.
32. Burns, J. C., Friedmann, T., Driever, W., Burrascano, M., and Yee, J. K. (1993). Vesicular stomatitis virus G glycoprotein-pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA 90: 8033-8037.
33. Poeschla, E. M., Wong-Staal, F., and Looney, D. J. (1998). Efficient transcluction of non-dividing human cells by feline immunodeficiency virus lentiviral vectors. Nat. Med. 4: 354-357.
34. Goldman, M. J., Lee, P. S., Yang, J. S., and Wilson, J. M. (1997). Lentiviral vectors for gene therapy of cystic fibrosis. Hum. Gene Ther. 8: 2261-2268.
35. Costello, E., et al. (2000). Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors. Gene Ther. 7: 596-604.
36. + cells via human immunodeficiency virus-based gene transfer vectors. Hum. Gene Ther. 10: 935-945.
37. Schroers, R., et al. (2000). Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol. Ther. 1: 171-179.
38. Park, F., Ohashi, K., Chiu, W., Naldini, L., and Kay, M. A. (2000). Efficient lentiviral transduction of liver requires cell cycling in vivo. Nat. Genet. 24: 49-52.
39. Scherr, M., Battmer, K., Blomer, U., Ganser, A., and Grez, M. (2001). Quantitative determination of lentiviral vector particle numbers by real-time PCR. BioTechniques 31: 520-526.
40. Trono, D. (1992). Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J. Virol. 66: 4893-4900.
41. Chang, L. J., Urlacher, V., Iwakuma, T., Cui, Y., and Zucali, J. (1999). Efficacy and safety analyses of a recombinant human immunodeficiency virus type 1-derived vector system. Gene Ther. 6: 715-728.
42. Haas, D. L., Case, S. S., Crooks, G. M., and Kohn, D. B. (2000). Critical factors influencing stable transduction of human CD34(+) cells with HIV-1-derived lentiviral vectors. Mol. Ther. 2: 71-80.
43. Pilling, A. M. (1999). The role of the toxicologic pathologist in the preclinical safety evaluation of biotechnology-derived pharmaceuticals. Toxicol. Pathol. 27: 678-688.
44. Woychik, R. P., Stewart, T. A., Davis, L. G., D'Eustachio, P., and Leder, P. (1985). An inherited limb deformity created by insertional mutagenesis in a transgenic mouse. Nature 318: 36-40.
45. McNeish, J. D., Scott, W. J., Jr., and Potter, S. S. (1988). Legless, a novel mutation found in PHT1-1 transgenic mice. Science 241: 837-839.
46. Case, S. S., et al. (1999). Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1 -based lentiviral vectors. Proc. Natl. Acad. Sci. USA 96: 2988-2993.
47. Richter, J., and Karlsson, S. (2001). Clinical gene therapy in hematology: past and future. Int. J. Hematol. 73: 162-169.
48. Kafri, T., van Praag, H., Ouyang, L., Gage, F. H., and Verma, I. M. (1999). A packaging cell line for lentivirus vectors. J. Virol. 73: 576-584.
49. Carlesso, N., Griffin, J. D., and Druker, B. J. (1994). Use of a temperature-sensitive mutant to define the biological effects of the p2l0BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line. Oncogene 9: 149-156.